Editor's Note: Relates to: 'Immuno-antibiotics: targeting microbial metabolic pathways sensed by unconventional T cells'.

We would like to alert readers to the recent retraction of one of the papers (Singh et al . [ref. 22]) cited in this review, which advocated the use of IspH inhibitors as ‘immuno-antibiotics’. The authors of the review discuss some of the findings by Singh et al . in the text and make reference to the work in Table 1 and Figure 2. Despite the retraction of this paper from the literature, the Editors at Immunotherapy Advances agree with Eberl et al . that there is a large body of complementary evidence in the literature demonstrating that the MEP pathway is an attractive target for the devel-opment of novel antibiotics and that manipulation of the MEP pathway has a direct effect on anti-microbial γδ T cell responses. As such we are confident that this retraction does not affect the validity of their article.